These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21859734)

  • 1. Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.
    Sanchorawala V; Quillen K; Sloan JM; Andrea NT; Seldin DC
    Haematologica; 2011 Dec; 96(12):1890-2. PubMed ID: 21859734
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.
    Labidi SI; Sebban C; Ghesquières H; Nicolas EV; Biron P
    Int J Hematol; 2008 Oct; 88(3):291-293. PubMed ID: 18696182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
    Miyamoto T; Yoshimoto G; Kamimura T; Muta T; Takashima S; Ito Y; Shiratsuchi M; Choi I; Kato K; Takenaka K; Iwasaki H; Takamatsu Y; Teshima T; Akashi K
    Int J Hematol; 2013 Sep; 98(3):337-45. PubMed ID: 23877150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy.
    Huang W; Li J; Li H; Kang W; Bo J; Zhao Y; Gao C; Zhou D; Yu L
    Leuk Lymphoma; 2012 Dec; 53(12):2507-10. PubMed ID: 22512306
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
    Roussel M; Moreau P; Huynh A; Mary JY; Danho C; Caillot D; Hulin C; Fruchart C; Marit G; Pégourié B; Lenain P; Araujo C; Kolb B; Randriamalala E; Royer B; Stoppa AM; Dib M; Dorvaux V; Garderet L; Mathiot C; Avet-Loiseau H; Harousseau JL; Attal M;
    Blood; 2010 Jan; 115(1):32-7. PubMed ID: 19884643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.
    Basak GW; Jaksic O; Koristek Z; Mikala G; Mayer J; Masszi T; Labar B; Wiktor-Jedrzejczak W;
    Am J Hematol; 2011 Jul; 86(7):550-3. PubMed ID: 21674573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
    Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD; Lechowicz MJ; Khoury HJ; Flowers CR; Waller EK
    Clin Cancer Res; 2010 Oct; 16(20):5079-86. PubMed ID: 20739431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.
    Thompson PA; Prince HM; Seymour JF; Ritchie D; Stokes K; Burbury K; Wolf M; Peinert S; Joyce T; Harrison SJ
    Bone Marrow Transplant; 2011 May; 46(5):764-5. PubMed ID: 20676149
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
    Freytes CO; Toro JJ; Yeh RF; Stadtmauer EA; Ratanatharathorn V; Akpek G; Sahovic E; Tricot GJ; Shaughnessy PJ; White DJ; Rodriguez TE; Solomon SR; Yu LH; Zhao C; Patil S; Armstrong E; Smith A; Elekes A; Kato K; Reece DE
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):1949-57. PubMed ID: 25139216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.
    Lee JY; Lim SH; Kim SJ; Lee GY; Lee JE; Choi JO; Kim JS; Kim HJ; Lee SY; Min JH; Jeon ES; Kim K
    Amyloid; 2014 Dec; 21(4):261-6. PubMed ID: 25248716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
    Caballero-Velázquez T; López-Corral L; Encinas C; Castilla-Llorente C; Martino R; Rosiñol L; Sampol A; Caballero D; Serrano D; Heras I; San Miguel J; Pérez-Simón JA
    Br J Haematol; 2013 Aug; 162(4):474-82. PubMed ID: 23772672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
    Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fifty years of melphalan use in hematopoietic stem cell transplantation.
    Bayraktar UD; Bashir Q; Qazilbash M; Champlin RE; Ciurea SO
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):344-56. PubMed ID: 22922522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.
    Doo NW; Thompson PA; Prince HM; Seymour JF; Ritchie D; Stokes K; Burbury K; Wolf M; Joyce T; Harrison SJ
    Leuk Lymphoma; 2013 Jul; 54(7):1465-72. PubMed ID: 23121086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
    Huang X; Wang Q; Chen W; Zeng C; Chen Z; Gong D; Zhang H; Liu Z
    BMC Med; 2014 Jan; 12():2. PubMed ID: 24386911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.
    Fenk R; Liese V; Neubauer F; Bruns I; Kondakci M; Balleisen S; Saure C; Schröder T; Haas R; Kobbe G
    Leuk Lymphoma; 2011 Aug; 52(8):1455-62. PubMed ID: 21657961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.